SULF2 (Sulfatase 2)

Functionally, SULF1 depletion impaired melanoma cell migration and invasion in vitro and reduced spontaneous metastasis in an orthotopic xenograft model. Together, these findings define an epigenetic axis linking chromatin regulation to extracellular glycan remodeling and identify HS-modifying enzymes as candidate targets to limit melanoma metastasis.

Cross-organ single-cell integration prioritizes liver-selective stromal circuitry and nominates hepatocyte-FB axes (HGF-MET, AGT-AGTR1B) as plausible links between fibrogenic remodeling and a pro-tumorigenic niche, yielding testable hypotheses at the interface of regeneration, RAS biology, and tumor initiation.

These findings highlight the importance of CAF-derived SULF1 in regulating tumor invasion and suggest that SULF1 is a promising therapeutic target in HNSCC.

Given the implication of HSulfs in diverse physiological and pathological contexts, including cancer, the HD presents a promising therapeutic target for the selective inhibition of endosulfatase activity. We discuss the challenges and perspectives in targeting intrinsically disordered regions (IDRs) in GAG-binding proteins, and highlight how the HD of HSulfs provides a paradigmatic example of non-canonical domains orchestrating fine-tuned GAG editing in the extracellular matrix.

Upon incubation with Sulf-2-containing culture supernatant from pancreatic cancer cells, MAR-S exhibited a significant increase in fluorescence at approximately 540 nm. Notably, MAR-S allowed for time-lapse monitoring of endogenous Sulf-2 activity in living cancer cells overexpressing Sulf-2, demonstrating its potential as a valuable tool for Sulf-2-related cancer diagnostics and therapeutic research.

Functional assays were performed with the antineoplastic drug doxurubicin and the WNT3a inhibitor, ipafricept. When the in vivo cell-ECM interactions were mimicked in the hyaluronic acid-based hydrogel, Doxorubicin and ipraficept were particularly effective against the GPC3-silenced RMS cells. This study lay the fundation for a different therapeutic approach against pediatric RMS that aim to dysregulate the protein microenvironment not only beat the cancer cells.

Furthermore, we would summarize the potential applications and limitations of Sulf-2 as a target in combining therapies for human tumors, providing insights that could be instrumental in advancing targeted cancer treatments. Our comprehensive review will shed light on the multifaceted role and therapeutic potential of Sulf-2 in human tumor biology.

Results from mass spectrometry-hydroxyl radical protein footprinting and repulsive scaling replica exchange molecular dynamics indicate similarities in the binding of heparin and HfFucCS oligosaccharides to both the catalytic and hydrophilic domains of Sulf-2. These findings reveal the unique inhibitory properties of a structurally distinct marine glycosaminoglycan, supporting its further investigation as a selective and effective inhibitor for Sulf-2-associated cancer events.

The highest incidence and cancer-related mortality rate among women worldwide is due to breast cancer. The co-treatment of chemotherapy and OKN-007 also attenuated cancer-initiating cells. This data implies that the combination of SULF2 inhibitors with chemotherapy augments eATP and decreases cell viability of TNBC greater than chemotherapy alone.

Pre-analytic evaluation of the manufacturer's recommended 20% tumor content cut-off is essential to ensure valid results. The Idylla MSI assay offers several advantages over other PCR-based assays including minimal hands-on time, rapid turn-around-time, no requirement for a paired normal sample and the use of FFPE directly without an extraction step.

Our goal was to evaluate the preclinical efficacy and mechanism of action of the anticancer drug Oklahoma Nitrone-007 (OKN-007) alone and in combination with carboplatin and paclitaxel in endometrial cancer. SIGNIFICANCE STATEMENT: Women with advanced and recurrent endometrial cancer have limited therapeutic options. Oklahoma Nitrone-007 (OKN-007), which has minimal toxicity and is currently being evaluated in early-phase clinical trials for the treatment of cancer, is a potential new strategy for the treatment of endometrial cancer.

Nine platelet-related prognostic genes identified as prognostic signatures for glioma were closely associated with the TME and may aid in directing the clinical treatment and prognosis of gliomas.